Skip to main content
CARMAT logo

CARMAT — Investor Relations & Filings

Ticker · ALCAR ISIN · FR0010907956 LEI · 969500ARXACM0P0KH333 PA Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2014-02-12 Earnings Release
Country FR France
Listing PA ALCAR

About CARMAT

https://www.carmatsa.com/en/

CARMAT is a medical technology company that designs, develops, and markets the Aeson® total artificial heart. This bioprosthetic device provides a therapeutic solution for patients suffering from end-stage biventricular heart failure. Aeson® is designed to replace the native heart, primarily as a bridge to transplantation for eligible patients. A key feature of the device is its self-regulation capability, which uses embedded sensors and biocompatible materials to automatically adapt blood flow based on the patient's physiological needs, thereby mimicking the function of a natural heart.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Earnings Release Classification · 1% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and announces "Résultats annuels 2013" (Annual Results 2013). It contains key financial highlights (cash position, net result) and operational milestones for the fiscal year ended December 31, 2013. This structure—a brief announcement summarizing the period's performance immediately following the close of the fiscal year—is characteristic of an Earnings Release (ER), which provides the initial announcement of periodical financial results (key highlights only). Although it discusses annual results, it is presented as a press release summary, not the comprehensive 10-K filing itself. It is not a full transcript (CT), a detailed management discussion (MDA), or a formal audit report (AR). Therefore, ER is the most appropriate classification. FY 2013
2014-02-12 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and announces the publication of the "5 ème Lettre aux actionnaires" (5th Letter to Shareholders). It provides a brief summary of the content (key figures from the first human implant) and directs the reader to a link to consult the full letter. Since the document itself is an announcement about the release of another document (the Letter to Shareholders), and it is short, it fits the criteria for a Report Publication Announcement (RPA). While 'Letter to Shareholders' might suggest an Investor Presentation (IP) or Management Report (MDA), the format here is a short press release announcing the availability of that material, making RPA the most accurate classification based on the 'MENU VS MEAL' rule.
2014-02-03 French
Communicated under the obligation to provide permanent information / Other communications
Report Publication Announcement Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces the "publication of its 5th Shareholder Newsletter." It provides a brief summary of the newsletter's content and directs the reader to a link to read the full document. According to Rule 2 (The "MENU VS MEAL" Rule), a short announcement stating that a report has been published, often with a link, should be classified as a Report Publication Announcement (RPA), rather than the report itself. The content is not a full financial report (10-K, IR), an earnings release (ER), or a transcript (CT).
2014-02-03 English
Rachat d'actions / Contrat de liquidité Information relative au contrat de liquidité
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and provides a semi-annual update on a liquidity contract ('Bilan semestriel du contrat de liquidité') as of December 31, 2013, comparing it to the previous update on June 30, 2013. This is a routine disclosure regarding the company's market making/liquidity arrangement, detailing the number of shares and cash balance held by the liquidity provider (DSF Markets). This type of periodic disclosure, which is not a full financial report (like 10-K or IR) but rather a specific operational/financing update, fits best under Capital/Financing Update (CAP) or potentially a general Regulatory Filing (RNS). Since it specifically details the status of a financing/market support mechanism, CAP is a strong candidate. However, given the context of routine updates on financing arrangements, and the fact that it is a press release announcing specific figures rather than a comprehensive report, it is most closely aligned with Capital/Financing Update (CAP) or a general Regulatory Filing (RNS). Given the options, updates on financing arrangements like liquidity contracts are often grouped under Capital/Financing Update (CAP). It is short and announces specific figures, not a full report, so RPA/RNS are possibilities, but CAP is more specific to the content (liquidity contract status). I will classify it as CAP due to the explicit mention of the 'contrat de liquidité'.
2014-01-06 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is explicitly titled 'PRESS RELEASE' and announces a significant corporate event: the 'First-in-man implantation of CARMAT's bioprosthetic artificial heart' on December 20, 2013. This is a major operational and clinical milestone announcement, not a routine periodic financial filing (like 10-K, IR, or ER). It contains operational updates, quotes from the CEO, and standard disclaimers typical of a press release regarding clinical progress. Since there is no specific category for 'Press Release' or 'Clinical Update,' and it is not a formal regulatory filing like a 10-K or an earnings release (ER), the most appropriate general category for a significant, non-financial regulatory/corporate announcement that doesn't fit elsewhere is 'Regulatory Filings' (RNS), as it serves as a public disclosure mechanism. However, given the nature of the announcement (a major operational/clinical breakthrough), it is often categorized as a general corporate announcement. Since RNS is the designated fallback for miscellaneous regulatory announcements, it is the best fit among the provided options for a non-standard, material corporate disclosure.
2013-12-20 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and announces a significant corporate event: the first human implantation of CARMAT's artificial heart. It provides key details, quotes from management, background information on the company, and contact details for media/investor relations. This structure is characteristic of an immediate public announcement rather than a comprehensive periodic report (like 10-K or IR) or a formal regulatory filing like a proxy statement or earnings release. Since there is no specific category for a general press release announcing a major operational milestone, and it is not a transcript (CT), a formal financial report (IR, 10-K), or a management discussion (MDA), the most appropriate fallback category is Regulatory Filings (RNS), which often serves as a catch-all for significant, non-standard announcements made to the public/market, especially when issued by a European company.
2013-12-20 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.